 Daniel Sherbenou
Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 18 | 2025 | 98 | 8.420 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1257 | 2.430 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 637 | 1.630 |
Why?
| | Immunoconjugates | 3 | 2020 | 87 | 1.580 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 94 | 1.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1356 | 1.270 |
Why?
| | Thalidomide | 3 | 2024 | 28 | 1.210 |
Why?
| | Interferon Regulatory Factors | 2 | 2024 | 31 | 1.080 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2024 | 116 | 1.030 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2010 | 60 | 0.970 |
Why?
| | Osteolysis | 1 | 2025 | 15 | 0.950 |
Why?
| | Immunoglobulin Light Chains | 1 | 2025 | 36 | 0.950 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 784 | 0.940 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 18 | 0.920 |
Why?
| | Piperazines | 5 | 2010 | 310 | 0.880 |
Why?
| | Pyrimidines | 5 | 2010 | 374 | 0.840 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 850 | 0.820 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 1875 | 0.750 |
Why?
| | Hydrazines | 1 | 2021 | 27 | 0.730 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2024 | 147 | 0.730 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 519 | 0.720 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.710 |
Why?
| | Membrane Cofactor Protein | 2 | 2018 | 12 | 0.710 |
Why?
| | ADP-ribosyl Cyclase 1 | 4 | 2024 | 36 | 0.680 |
Why?
| | Triazoles | 1 | 2021 | 125 | 0.670 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 687 | 0.650 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 386 | 0.620 |
Why?
| | Antibodies, Neoplasm | 2 | 2018 | 30 | 0.580 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 152 | 0.490 |
Why?
| | Immunotherapy | 2 | 2017 | 473 | 0.460 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 2699 | 0.460 |
Why?
| | Mutation | 4 | 2010 | 3338 | 0.450 |
Why?
| | Dexamethasone | 3 | 2021 | 316 | 0.430 |
Why?
| | Antibodies, Bispecific | 2 | 2024 | 32 | 0.360 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1144 | 0.350 |
Why?
| | src Homology Domains | 1 | 2010 | 33 | 0.340 |
Why?
| | Benzamides | 6 | 2018 | 168 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 695 | 0.330 |
Why?
| | Humans | 30 | 2025 | 114080 | 0.330 |
Why?
| | Imatinib Mesylate | 5 | 2010 | 63 | 0.320 |
Why?
| | Transplantation Conditioning | 3 | 2020 | 149 | 0.310 |
Why?
| | Oligopeptides | 2 | 2021 | 234 | 0.300 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 91 | 0.300 |
Why?
| | Sequence Deletion | 1 | 2008 | 166 | 0.290 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 393 | 0.280 |
Why?
| | Mutant Proteins | 1 | 2007 | 95 | 0.270 |
Why?
| | B-Cell Maturation Antigen | 1 | 2024 | 4 | 0.230 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 660 | 0.220 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2024 | 11 | 0.220 |
Why?
| | Male | 13 | 2025 | 55420 | 0.220 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 172 | 0.210 |
Why?
| | Bone Marrow | 3 | 2020 | 243 | 0.210 |
Why?
| | Animals | 10 | 2025 | 31570 | 0.210 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 185 | 0.210 |
Why?
| | Cell Proliferation | 5 | 2020 | 2173 | 0.210 |
Why?
| | Lymphoma | 1 | 2024 | 176 | 0.210 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 87 | 0.210 |
Why?
| | Mice | 7 | 2025 | 14847 | 0.200 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 388 | 0.200 |
Why?
| | Sulfonamides | 1 | 2025 | 444 | 0.190 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 327 | 0.190 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1032 | 0.190 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 212 | 0.180 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2020 | 53 | 0.170 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 41 | 0.170 |
Why?
| | Aged | 9 | 2020 | 18973 | 0.170 |
Why?
| | Heterografts | 1 | 2020 | 117 | 0.170 |
Why?
| | Primary Cell Culture | 1 | 2020 | 148 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 181 | 0.170 |
Why?
| | Drug Synergism | 1 | 2020 | 315 | 0.170 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 377 | 0.170 |
Why?
| | Prognosis | 2 | 2025 | 3315 | 0.160 |
Why?
| | Endoribonucleases | 1 | 2019 | 62 | 0.160 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 845 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 926 | 0.160 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.150 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 85 | 0.140 |
Why?
| | Female | 11 | 2024 | 59349 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2021 | 9051 | 0.140 |
Why?
| | Prostate | 1 | 2018 | 157 | 0.140 |
Why?
| | Middle Aged | 8 | 2020 | 26621 | 0.140 |
Why?
| | Melphalan | 1 | 2017 | 29 | 0.140 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 222 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2020 | 1075 | 0.140 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 159 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2016 | 66 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1735 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 146 | 0.130 |
Why?
| | Salvage Therapy | 1 | 2017 | 127 | 0.130 |
Why?
| | Protein Structure, Tertiary | 3 | 2007 | 796 | 0.130 |
Why?
| | Gene Dosage | 1 | 2016 | 129 | 0.130 |
Why?
| | Adult | 8 | 2020 | 30395 | 0.130 |
Why?
| | Immunologic Factors | 1 | 2018 | 217 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 347 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1117 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6307 | 0.110 |
Why?
| | Signal Transduction | 3 | 2020 | 4501 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2018 | 787 | 0.100 |
Why?
| | Recurrence | 3 | 2019 | 925 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 913 | 0.090 |
Why?
| | Immunoblotting | 2 | 2008 | 282 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2023 | 12521 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2008 | 4392 | 0.080 |
Why?
| | Protein Kinases | 1 | 2010 | 304 | 0.070 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2008 | 34 | 0.070 |
Why?
| | Philadelphia Chromosome | 1 | 2007 | 15 | 0.070 |
Why?
| | Cell Line | 2 | 2010 | 2629 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 210 | 0.070 |
Why?
| | Janus Kinase 2 | 1 | 2006 | 31 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2007 | 80 | 0.070 |
Why?
| | Myeloproliferative Disorders | 1 | 2006 | 26 | 0.070 |
Why?
| | Codon | 1 | 2007 | 85 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 155 | 0.070 |
Why?
| | Remission Induction | 1 | 2007 | 233 | 0.070 |
Why?
| | Treatment Refusal | 1 | 2007 | 85 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-abl | 1 | 2005 | 7 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 373 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 237 | 0.060 |
Why?
| | Models, Molecular | 1 | 2010 | 1368 | 0.060 |
Why?
| | Protein Conformation | 1 | 2008 | 803 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2007 | 465 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 20 | 0.060 |
Why?
| | src-Family Kinases | 1 | 2005 | 88 | 0.060 |
Why?
| | Mutation, Missense | 1 | 2006 | 294 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 924 | 0.060 |
Why?
| | Survival Analysis | 2 | 2018 | 1206 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1559 | 0.060 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 3862 | 0.040 |
Why?
| | Cohort Studies | 1 | 2010 | 4885 | 0.040 |
Why?
| | Young Adult | 2 | 2018 | 10459 | 0.040 |
Why?
| | X-Box Binding Protein 1 | 1 | 2019 | 7 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2550 | 0.040 |
Why?
| | Bortezomib | 1 | 2019 | 41 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 44 | 0.040 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2019 | 34 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 92 | 0.040 |
Why?
| | Androstenes | 1 | 2018 | 11 | 0.040 |
Why?
| | Therapeutics | 1 | 2018 | 12 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2018 | 50 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2018 | 51 | 0.040 |
Why?
| | Phenylthiohydantoin | 1 | 2018 | 40 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 268 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 21 | 0.040 |
Why?
| | Vidarabine | 1 | 2018 | 26 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 5 | 0.040 |
Why?
| | Myocarditis | 1 | 2019 | 93 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 72 | 0.040 |
Why?
| | Nitriles | 1 | 2018 | 149 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 714 | 0.040 |
Why?
| | Wnt Proteins | 1 | 2018 | 134 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 725 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2017 | 183 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 813 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 175 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1078 | 0.030 |
Why?
| | beta Catenin | 1 | 2018 | 218 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 613 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 428 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1024 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1638 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1624 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 2006 | 338 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2371 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 533 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3397 | 0.020 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2006 | 5 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 12 | 0.020 |
Why?
| | Polycythemia | 1 | 2006 | 23 | 0.020 |
Why?
| | Receptors, Erythropoietin | 1 | 2006 | 22 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 70 | 0.020 |
Why?
| | Clone Cells | 1 | 2006 | 247 | 0.020 |
Why?
| | Erythropoietin | 1 | 2006 | 72 | 0.020 |
Why?
| | Time Factors | 2 | 2006 | 6077 | 0.020 |
Why?
| | Phosphotyrosine | 1 | 2005 | 33 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 266 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 74 | 0.020 |
Why?
| | Dasatinib | 1 | 2005 | 45 | 0.020 |
Why?
| | Thiazoles | 1 | 2005 | 110 | 0.020 |
Why?
| | Spleen | 1 | 2006 | 485 | 0.010 |
Why?
| | Point Mutation | 1 | 2005 | 216 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 863 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 452 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 287 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1144 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2005 | 428 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1128 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1837 | 0.010 |
Why?
| | Stem Cells | 1 | 2005 | 541 | 0.010 |
Why?
|
|
Sherbenou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|